SCM
NVCT icon

Soleus Capital Management’s Nuvectis Pharma NVCT Stock Holding History

Soleus Capital Management’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4M Buy
+1,000,000
New +$11.2M 0.63% 42

Other funds holding NVCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
AWM
Austin Wealth Management Austin, Texas $473M AUM 18.73% 1-Year Est. Return

Soleus Capital Management's NVCT Position: Q2 2026 in Review

Soleus Capital Management opened a new position in Nuvectis Pharma (NVCT) in Q2 2026: 1,000,000 shares worth $18.4M. The stake represents 0.63% of the portfolio and ranks #42 among its holdings.

36 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Soleus Capital Management held 1,000,000 shares of Nuvectis Pharma worth $18.4M as of Q2 2026.
  • Nuvectis Pharma was a new Soleus Capital Management position in Q2 2026.
  • Nuvectis Pharma made up 0.63% of Soleus Capital Management's portfolio in Q2 2026, its #42 holding.
  • 36 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.